TMED2通过向KEAP1-Nrf2通路诱导乳腺癌中的西斯普拉丁耐药性
Chen Liang1, Han-Yong Zhang2, Yi-Qian Wang1
1College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, 430070, China.
Current medical science
|August 24, 2023
概括
含有2 (TMED2) 的跨膜emp24蛋白传输域通过激活Nrf2通路,促进乳腺癌中对西斯普拉丁的耐药性. 这一发现为克服乳腺癌治疗中的耐药性提供了新的见解.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 西斯是一种主要的乳腺癌治疗方法,但耐药性限制了它的有效性.
- 了解青抗性的新型分子机制对于改善患者的治疗结果至关重要.
研究的目的:
- 调查含有2 (TMED2) 的跨膜emp24蛋白传输域在乳腺癌中对西斯普拉丁耐药性的作用.
- 阐明 TMED2 影响药物耐药性的分子途径.
主要方法:
- 对TMED2和乳腺癌协会的TCGA数据库的分析.
- 在体外实验中使用MCF-7和MDA-MB-231细胞系进行实验.
- 西部涂抹,实时PCR,CCK-8和TUNEL测试用于评估TMED2功能和分子机制.
主要成果:
- TMED2在乳腺癌中过度表达,与预后不佳相关.
- TMED2通过促进KEAP1的无化,激活Nrf2.2来增强西斯普拉丁的耐药性.
- 激活的Nrf2导致药物耐药性基因 (HO-1,NQO1) 的表达增加.
结论:
- TMED2代表了一种新型的分子标,影响乳腺癌中西斯普拉丁耐药性.
- TMED2-KEAP1-Nrf2通路是驱动化学抵抗的一个关键机制.
- 这些发现为开发克服西斯普拉丁耐药性的策略提供了理论基础.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


